Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study

被引：0
|
作者：
Smit, E. [1 ]
Ahn, M-J [2 ]
Dagogo-Jack, I. [3 ]
Felip, E. [4 ]
Gelsomino, F. [5 ]
Johnson, B. [6 ]
Johnson, M. [7 ]
Negrao, M. V. [8 ]
Offin, M. [9 ]
Ramalingam, S. [10 ]
Sanborn, R. [11 ]
Tsao, A. [8 ]
Wilner, K. [12 ]
Alcasid, A. [13 ]
Usari, T. [14 ]
Zhang, X. [15 ]
Riely, G. [9 ]
机构：
[1] Leiden Univ, Med Ctr, Leiden, Netherlands
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[3] Massachusetts Gen Hosp, Boston, MA USA
[4] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[5] IRCCS Azienda Osped Univ Bologna, Bologna, Italy
[6] Dana Farber Canc Inst, Boston, MA USA
[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[11] Providence Canc Inst, Earle A Chiles Res Inst, Providence, RI USA
[12] Pfizer, La Jolla, CA USA
[13] Pfizer, Collegeville, PA USA
[14] Pfizer, Milan, Italy
[15] Pfizer, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
non-small cell lung cancer; encorafenib; binimetinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA06.13
引用
收藏
页码：S77 / S78
页数：2
相关论文
共 50 条
  • [31] Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real World Setting
    Auliac, J. B.
    Bayle, S.
    Do, P.
    Legarff, G.
    Guisier, F.
    Roa, M.
    Falchero, L.
    Huchon, E.
    Quere, G.
    Jeannin, G.
    Doubre, H.
    Baud, M.
    Hobeika, J.
    Chouaid, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S857 - S857
  • [32] Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
    Subbiah, V
    Kreitman, R. J.
    Wainberg, Z. A.
    Cho, J. Y.
    Schellens, J. H. M.
    Soria, J. C.
    Wen, P. Y.
    Zielinski, C. C.
    Cabanillas, M. E.
    Boran, A.
    Ilankumaran, P.
    Burgess, P.
    Salas, T. Romero
    Keam, B.
    ANNALS OF ONCOLOGY, 2022, 33 (04) : 406 - 415
  • [33] A Phase Ib/II Study of WNT974+Encorafenib plus Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
    Tabernero, Josep
    Van Cutsem, Eric
    Garralda, Elena
    Tai, David
    De Braud, Filippo
    Geva, Ravit
    van Bussel, Mark T. J.
    Fiorella Dotti, Katia
    Elez, Elena
    de Miguel, Maria J.
    Litwiler, Kevin
    Murphy, Danielle
    Edwards, Michelle
    Morris, Van Karlyle
    ONCOLOGIST, 2023, : 230 - 238
  • [34] BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs, choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer
    Kopetz, S.
    Crothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Gollerkeri, F.
    Maharry, K.
    Loupakis, F.
    Hong, Y.
    Steeghs, F.
    Guren, T.
    Arkenau, H.
    Garcia Alfonso, P.
    Sandor, V.
    Christy-Bittel, J.
    Anderson, L.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [35] ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BIM), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC)
    Grothey, A.
    Yaeger, R.
    Paez, D.
    Tabernero, J.
    Taieb, J.
    Yoshino, T.
    Groc, M.
    Vedovato, J.
    Chetaille, E.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2019, 30 : 109 - 109
  • [36] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
    Tabernero, J.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. Sang
    Steeghs, N.
    Guren, T. K.
    Arkenau, H-T.
    Garcia-Alfonso, P.
    Gollerkeri, A.
    Pickard, M.
    Maharry, K.
    Christy-Bittel, J. L.
    Anderson, L.
    Kopetz, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 868 - 868
  • [37] Dramatic Response to Sequential BRAF Inhibition in BRAF V600E-Mutant Metastatic Lung Adenocarcinoma
    Jonna, Sushma
    Giaccone, Giuseppe
    Filice, Ross
    Kramer, Jenna
    Subramaniam, Deepa S.
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 6
  • [38] Encorafenib (enco) plus binimetinib (bini) plus pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).
    Schadendorf, Dirk
    Dummer, Reinhard
    Robert, Caroline
    Ribas, Antoni
    Sullivan, Ryan J.
    Panella, Timothy J.
    McKean, Meredith
    Santos, Edgardo S.
    Clancy, Jill S.
    Thakur, Mahgull Nazar
    Polli, Anna
    Di Pietro, Alessandra
    Ascierto, Paolo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Encorafenib and binimetinib with or without nivolumab in treating patients with metastatic radioiodine refractory BRAF V600 mutant thyroid cancer.
    Taylor, Matthew H.
    Leidner, Rom S.
    Bell, Richard Bryan
    Fox, Bernard
    Xiao, Hong
    Couey, Marcus
    Baker, Andrew
    Morris, George
    Rushforth, Lessli
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients
    Indini, Alice
    Mandala, Mario
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (10) : 1229 - 1236
12345